Elevation of KL-6 serum levels in clinical trials of tumor necrosis factor inhibitors in patients with rheumatoid arthritis : a report from the Japan College of Rheumatology Ad Hoc Committee for Safety of Biological DMARDs
スポンサーリンク
概要
- 論文の詳細を見る
- 2013-03-01
著者
-
Miyasaka Nobuyuki
Global Center Of Excellence (gcoe) Program Department Of Medicine And Rheumatology Graduate School O
-
KOIKE Takao
Sapporo Medical Center NTT EC
-
MIYASAKA Nobuyuki
Global Center of Excellence Program, International Research Center for Molecular Science in Tooth and Bone Diseases, Tokyo Medical and Dental University
-
TAKAMURA Akito
The Ad Hoc Committee for the Safety of Biological DMARDs, Japan College of Rheumatology
-
SETO Yohei
The Ad Hoc Committee for the Safety of Biological DMARDs, Japan College of Rheumatology
-
KAMEDA Hideto
The Ad Hoc Committee for the Safety of Biological DMARDs, Japan College of Rheumatology
-
NAGASAWA Hayato
The Ad Hoc Committee for the Safety of Biological DMARDs, Japan College of Rheumatology
-
HARIGAI Masayoshi
The Ad Hoc Committee for the Safety of Biological DMARDs, Japan College of Rheumatology
-
ATSUMI Tatsuya
The Ad Hoc Committee for the Safety of Biological DMARDs, Japan College of Rheumatology
-
DOHI Makoto
The Ad Hoc Committee for the Safety of Biological DMARDs, Japan College of Rheumatology
-
HIRATA Shintaro
The Ad Hoc Committee for the Safety of Biological DMARDs, Japan College of Rheumatology
関連論文
- Therapeutic effect of D1-like dopamine receptor antagonist on collagen-induced arthritis of mice
- Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients : postmarketing surveillance report of the first 3,000 patients
- Elevation of KL-6 serum levels in clinical trials of tumor necrosis factor inhibitors in patients with rheumatoid arthritis : a report from the Japan College of Rheumatology Ad Hoc Committee for Safety of Biological DMARDs
- A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients : a report from the Ad Hoc Committee for Safety of Biological DMARDs of the Japan College of Rheumatology